Results from the National Sepsis Practice Survey: use of drotrecogin α (activated) and other therapeutic decisions.

Journal of Critical Care
James M O'BrienStanley Lemeshow

Abstract

We sought to evaluate factors associated with choices about provided care for patients with septic shock, including the use of drotrecogin α (activated) (DAA). We administered a mail-based survey to a random sample of intensivists. Study vignettes presented patients with septic shock with identical severity of illness scores but different ages, body mass indices, and comorbidities. Respondents estimated outcomes and selected care beyond standardized initial care (eg, antibiotics) for each hypothetical patient. For most vignettes (99.1%), respondents added care, most commonly low tidal volume ventilation (87.6%) and enteral nutrition (73.3%). Choosing to administer DAA was not associated with predictions about mortality or bleeding. Vignettes with early-stage lung cancer were less likely to receive DAA. Time since medical school graduation was also associated with lower odds of selecting DAA. Most respondents (52.6%) chose identical care for all 4 completed vignettes. There was wide variability in the therapeutic choices of respondents. The use of DAA was not associated with perceived risk of mortality or bleeding, as recommended by consensus guidelines. Physicians appear to base treatment decisions in septic shock on a consiste...Continue Reading

References

Nov 1, 1992·Archives of Internal Medicine·J RapoportD Teres
Apr 4, 1992·JAMA : the Journal of the American Medical Association·S GreenfieldJ E Ware
Oct 26, 1989·The New England Journal of Medicine·J E WennbergT A Bubolz
Aug 1, 1995·Critical Care Medicine·J RapoportS Hamilton
Mar 3, 1994·The New England Journal of Medicine·H G WelchW P Welch
Oct 2, 1996·JAMA : the Journal of the American Medical Association·D C AngusM R Pinsky
Nov 22, 1997·Journal of Clinical Epidemiology·D A AschN A Christakis
May 18, 2000·JAMA : the Journal of the American Medical Association·J RapoportS Lemeshow
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
Sep 27, 2002·The New England Journal of Medicine·H Shaw WarrenRobert S Munford
Apr 18, 2003·The New England Journal of Medicine·Greg S MartinMarc Moss
Mar 5, 2004·Intensive Care Medicine·R Phillip DellingerM M Levy
Feb 16, 2005·Annals of Internal Medicine·Niteesh K ChoudhryStephen B Soumerai
Sep 30, 2005·The New England Journal of Medicine·Edward AbrahamUNKNOWN Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group
Oct 20, 2006·The New England Journal of Medicine·Peter Q EichackerRobert L Danner
Mar 14, 2007·Lancet·Simon NadelUNKNOWN REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group
Jul 11, 2007·Archives of Internal Medicine·Gregory B DietteCynthia Rand
Dec 22, 2007·Journal of Palliative Medicine·Allan Garland, Alfred F Connors
Dec 26, 2007·Critical Care Medicine·R Phillip DellingerUNKNOWN World Federation of Societies of Intensive and Critical Care Medicine
Jan 17, 2008·Chest·Yen-Yuan ChenAllan Garland
Sep 4, 2008·Critical Care Medicine·Frank M BrunkhorstUNKNOWN German Sepsis Competence Network (SepNet)
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jeffrey M DurthalerJoseph A Johnston
Jun 25, 2009·Critical Care : the Official Journal of the Critical Care Forum·James M O'BrienStanley Lemeshow

❮ Previous
Next ❯

Citations

Feb 4, 2012·Journal of Critical Care·Tara LaguPeter K Lindenauer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

The New England Journal of Medicine
Edward AbrahamAdministration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group
© 2021 Meta ULC. All rights reserved